-+ 0.00%
-+ 0.00%
-+ 0.00%

Bausch + Lomb's BL1332 misses primary endpoint in Phase 2 ocular pain trial

PUBT·11/19/2026 21:19:47
Bausch + Lomb's BL1332 misses primary endpoint in Phase 2 ocular pain trial
  • Bausch + Lomb reported BL1332 missed its primary pain-relief endpoint in a Phase 2 trial following photorefractive keratectomy surgery.
  • Both doses showed numerically greater pain relief than vehicle; exploratory findings suggested faster corneal healing.
  • BL1332 was well tolerated, with no treatment-related adverse events or new safety signals.
  • The findings will inform FDA discussions on future development, including potential Phase 3 planning.
  • Management will present the results today at 5 p.m. ET.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch + Lomb Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611191615BIZWIRE_USPR_____20261118_BW969505) on November 19, 2026, and is solely responsible for the information contained therein.